Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervarix Reimbursement Will Be Key Challenge For Adoption, GSK Says

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline plans to submit a BLA for the human papillomavirus vaccine by year-end.

You may also be interested in...



Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says

GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.

Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says

GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.

Hycamtin Combo Therapy Approved For Late-Stage Cervical Cancer

GlaxoSmithKline’s topotecan demonstrates a survival benefit when used in combination with cisplatin, FDA says.

Related Content

Topics

UsernamePublicRestriction

Register

PS063806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel